IL-3 regulates the differentiation of pathogenic Th17 cells

Area of Science:

• Immunology
• Rheumatology
• Cell Biology

Background:

• T helper 17 (Th17) cells are crucial in rheumatoid arthritis (RA) pathogenesis.
• An imbalance between Th17 and regulatory T (Treg) cells contributes to RA and autoimmunity.
• Targeting Th17 cells presents a promising therapeutic strategy for RA.

Purpose of the Study:

• To investigate the role of Interleukin-3 (IL-3) in regulating Th17 and Treg cell differentiation.
• To explore the therapeutic potential of IL-3 in a mouse model of rheumatoid arthritis.

Main Methods:

• Investigated IL-3's effect on Th17 and Treg cell differentiation in vitro and in IL-2 knockout mice.
• Assessed the impact of IL-3 on pathogenic Th17 cell markers, cytokine secretion, and osteoclastogenesis.
• Examined the mechanism of IL-3 action on Th17 development via STAT3 phosphorylation.
• Evaluated IL-3 efficacy in a collagen-induced arthritis mouse model and in human Th17 cell differentiation.

Main Results:

• IL-3 inhibited Th17 cell differentiation and promoted Treg cell development in an IL-2-dependent manner.
• IL-3 reduced pathogenic Th17 cell populations (IL-17A+, TNF-α+, IFN-γ+, IL-23R+), GM-CSF, and IFN-γ secretion.
• IL-3 suppressed osteoclastogenesis and decreased arthritic scores in the RA mouse model.
• IL-3 inhibited STAT3 phosphorylation, a key pathway in Th17 development.
• IL-3 demonstrated inhibitory effects on human Th17 cell differentiation.

Conclusions:

• IL-3 modulates Th17 and Treg cell balance, suggesting a therapeutic role in RA.
• IL-3's mechanism involves inhibiting STAT3 phosphorylation and reducing pathogenic Th17 responses.
• IL-3 represents a novel therapeutic candidate for managing rheumatoid arthritis.